Understand the source comparison
SS-31 Safe Side Effects: Comparison of Trial Findings
Injection-site reactions 10–15% Mild (Grade 1) 24–48 hours Local immune response to subcutaneous peptide depot Expected with any SC peptide; reduced by slower injection rate and site rotation Chromaturia (dark urine) 10–20% at ≥4mg daily 48–72 hours post-cessa
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Injection-site reactions
- 10–15%
- Mild (Grade 1)
- 24–48 hours
- Local immune response to subcutaneous peptide depot
- Expected with any SC peptide; reduced by slower injection rate and site rotation
- Chromaturia (dark urine)
- 10–20% at ≥4mg daily
- 48–72 hours post-cessation
- Renal excretion of mobilised mitochondrial pigments during cardiolipin stabilisation
- Benign pharmacokinetic effect; no renal toxicity documented
- Dysgeusia (altered taste)
- 5–10%
- 24–72 hours
- Low-level CNS penetration affecting cranial nerve VII/IX taste signaling
- Transient and self-limiting; does not indicate neurotoxicity
- Headache
- 5–8%
- 12–24 hours
- Likely secondary to improved cerebral perfusion in vascular insufficiency populations
- Incidence matched placebo in most trials
- Fatigue
- 3–5%
- Variable (1–7 days)
- May reflect metabolic recalibration as ATP production normalises
- Rare; distinguished from disease-related fatigue by temporal association